Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL551405 | 0.98 | DDB1 (0.50) | DDB1CRBNALDH1A1LMNATDP1 | |
| Hydrochloric Acid SCHEMBL1809434 | 0.98 | DDB1 (0.50) | DDB1CRBNALDH1A1LMNATDP1 | |
| SCHEMBL1841706 | 0.98 | DDB1 (0.50) | DDB1CRBNALDH1A1LMNATDP1 | |
| Hydrochloric Acid SCHEMBL7530629 | 0.97 | DDB1 (0.49) | DDB1CRBNALDH1A1LMNATDP1 | |
| SCHEMBL1144346 | 0.97 | DDB1 (0.51) | DDB1CRBNALDH1A1LMNATDP1 | |
| SCHEMBL2542693 | 0.93 | DDB1 (0.54) | DDB1CRBNALDH1A1LMNATDP1 | |
| Hydrochloric Acid SCHEMBL2805409 | 0.92 | DDB1 (0.52) | DDB1CRBNALDH1A1LMNATDP1 | |
| SCHEMBL4803112 | 0.88 | DDB1 (0.44) | DDB1CRBNALDH1A1LMNATDP1 | |
| SCHEMBL6868302 | 0.86 | KMT2A (0.51) | DDB1CRBNALDH1A1LMNATDP1 | |
| SCHEMBL4615932 | 0.83 | LMNA (0.49) | LMNACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-2580193-B1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | CHROMA THERAPEUTICS LTD (GB) | 2016-07-20 | — | — | EP | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| EP-2580193-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS HSP90 INHIBTORS | Chroma Therapeutics Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| EP-0949244-A2 | Process for preparing hydroxamic acids | Pfizer Products Inc. (US) | 1999-10-13 | — | — | EP | disclosed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| US-5281617-A | Enzyme inhibitor | CORTECH, INC. (US) | 1994-01-25 | — | — | US | disclosed |
| US-5110799-A | Inhibition of viral ribonucleotide reductase | MERCK & CO., INC. (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0475898-A1 | Azacyclic compounds | CIBA-GEIGY AG (CH) | 1992-03-18 | — | — | EP | disclosed |
| EP-0412595-A1 | Antiherpetic agents | MERCK & CO. INC. (US) | 1991-02-13 | — | — | EP | disclosed |
| EP-0125106-B1 | 1-ACYLAMINO-1-CYCLOPENTANECARBOXYLIC ACIDS AND A PROCESS FOR PREPARING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1986-09-17 | — | — | EP | disclosed |
| EP-0125106-A1 | 1-Acylamino-1-cyclopentanecarboxylic acids and a process for preparing them | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-14 | — | — | EP | disclosed |
| US-4482572-A | 1-Acylamino-1-cyclopentanecarboxylic acids | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | DDB1 4819/4885CRBN 1881/4885ALDH1A1 378/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | DDB1 4819/4885CRBN 1881/4885ALDH1A1 378/4885 |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | DDB1 4318/4885CRBN 3965/4885ALDH1A1 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.